The Serum Laminin-γ2 Response Predicts the Treatment Efficacy of Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma

DOI
  • Oumi Ryosuke
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine
  • Kiyokawa Hirofumi
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine Division of Cancer Cell Research, Kanagawa Cancer Center Research Institute
  • Matsumoto Nobuyuki
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine
  • Okuse Chiaki
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine
  • Nakagawa Masatoshi
    Diagnostic Division, Abbot Japan Co., Ltd., Chiba, Japan. Division of Cancer Cell Research, Kanagawa Cancer Center Research Institute
  • Yoshida Eisaku
    Diagnostic Division, Abbot Japan Co., Ltd., Chiba, Japan.
  • Yoshimura Toru
    Diagnostic Division, Abbot Japan Co., Ltd., Chiba, Japan.
  • Seiki Motoharu
    Kanazawa University Graduate School of Medical Science
  • Koshikawa Naohiko
    Division of Cancer Cell Research, Kanagawa Cancer Center Research Institute
  • Yasuda Hiroshi
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine
  • Itoh Fumio
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine

Bibliographic Information

Other Title
  • 肝細胞癌に対するTACE後の治療効果判定における血清ラミニンγ2単鎖の有用性

Search this article

Description

<p>Background: Serum laminin-γ2 monomer (Ln-γ2m) is a potentially useful novel biomarker for the surveillance of hepatocellular carcinoma (HCC). We measured the serum Ln-γ2m levels before and after transarterial chemoembolization (TACE) as treatment for HCC and evaluated its diagnostic value in predicting HCC treatment efficacy.<br/>Methods: HCC patients treated with TACE at the St. Marianna University School of Medicine Hospital were enrolled between January 2013 and February 2018 (n=28; 19 men and 9 women; mean age: 70 years). Treatment effects were evaluated by dynamic contrast-enhanced computed tomography (CECT) a median 7 (range: 4–25) days after TACE using the modified Response Evaluation Criteria in Solid Tumors. Serum Ln-γ2m levels were measured by chemiluminescent immunoassay before and 7 days after TACE.<br/>Results: According to the CECT results, 5 patients had a complete response (CR), 11 a partial response (PR), 5 stable disease (SD), and 7 progressive disease (PD). In the effective therapeutic group (patients with CR or PR), serum Ln-γ2m levels were significantly decreased after TACE, by 60% with CR (3/5) and 36% with PR (4/11). Conversely, in PR cases in which therapy was ineffective, serum Ln-γ2m levels increased after TACE. In these cases, tumor progression was observed in CT images within 3 months. In the ineffective therapeutic group (patients with SD or PD), serum Ln-γ2m levels were significantly increased, by 100% with SD (5/5) and 86% with PD (6/7).<br/>Conclusion: The serum Ln-γ2m response may predict the treatment efficacy of TACE for advanced HCC.</p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top